EUVIMEDEUVIMED entdecken
Übersichtsarbeit

lncRNA EPB41L4A-AS1: A promising therapeutic target for aging and age-related diseases

Minghui Li, Tianzi Li, Xufei Zhang, Kun Li, Ziqiang Wang

Mechanisms of Ageing and Development · 2025-12 · 228 · 112118

DOI: 10.1016/j.mad.2025.112118 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Mechanisms of Ageing and Development, 2025-12. Verfasst von Minghui Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan 2…. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Aging, Neoplasms, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Shandong Province Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aging is a natural biological process characterized by progressive cellular and functional decline, significantly increasing susceptibility to age-related diseases. Long non-coding RNAs (lncRNAs) are increasingly recognized as critical regulators of cellular processes implicated in aging and age-related diseases. Among these, lncRNA erythrocyte membrane protein band 4.1 like 4 A antisense RNA 1 (EPB41L4A-AS1) has emerged as a key player with significant dysregulation across diverse age-related diseases including cancer, Alzheimer's disease (AD), and type 2 diabetes mellitus (T2DM). This review synthesizes current evidence showing that EPB41L4A-AS1 functions primarily as a tumor suppressor in many cancers, regulates neuronal autophagy and energy metabolism in AD, and modulates inflammatory and metabolic pathways in T2DM. Mechanistically, EPB41L4A-AS1 exerts its effects-via miRNA sponging, regulating key signaling pathways (NF-κB, Rho/ROCK), influencing histone modifications, and modulating cellular metabolism (glycolysis, glutaminolysis, NAD+/ATP synthesis). The compelling evidence positions EPB41L4A-AS1 as a promising, multi-faceted therapeutic target for mitigating the burden of age-related diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Long NoncodingAgingNeoplasmsDiabetes Mellitus, Type 2Alzheimer DiseaseHumansAnimalsSignal Transduction

Stichwörter der Autor:innen

Age-related diseasesAgingAlzheimer's diseaseCancerEPB41L4A-AS1LncRNAT2DM

Substanzen

RNA, Long Noncoding

Autor:innen und Institutionen

  • Department of Nuclear Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan 250014, China; Biomedical Sciences College & Shandong Medicinal Biotech…
  • Department of Nuclear Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan 250014, China.

Förderung

  • Shandong Province Natural Science Foundation

Zitieren

APA

Li, M., Li, T., Zhang, X., Li, K., & Wang, Z. (2025). lncRNA EPB41L4A-AS1: A promising therapeutic target for aging and age-related diseases. Mechanisms of Ageing and Development, 228, 112118. https://doi.org/10.1016/j.mad.2025.112118

Vancouver

Li M, Li T, Zhang X, Li K, Wang Z. lncRNA EPB41L4A-AS1: A promising therapeutic target for aging and age-related diseases. Mechanisms of Ageing and Development. 2025;228:112118. doi:10.1016/j.mad.2025.112118

BibTeX
@article{Li2025,
  author = {Li, Minghui and Li, Tianzi and Zhang, Xufei and Li, Kun and Wang, Ziqiang},
  title = {lncRNA EPB41L4A-AS1: A promising therapeutic target for aging and age-related diseases},
  journal = {Mechanisms of Ageing and Development},
  year = {2025},
  volume = {228},
  pages = {112118},
  doi = {10.1016/j.mad.2025.112118}
}
Kostenlos starten →